Chondrosarcoma Market Forecast 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Epidemiology, Statistics, Revenue, Therapies, Treatment, Companies by DelveInsight

(Albany, USA) Chondrosarcoma Market Summary
In 2023, the Chondrosarcoma market across the 7MM reached approximately USD 8.5 million in the US, with incident cases totaling around 2,300. This rare bone cancer, predominantly affecting adults over 40, is the second most common primary bone tumor after osteogenic sarcoma and is mainly diagnosed as Grade II. Despite its low prevalence, the market is anticipated to grow at a notable CAGR through 2034, driven by efforts from companies like Epizyme, Bayer, Eli Lilly, and others developing innovative therapies to address significant unmet needs. Current management heavily relies on wide surgical resection, as conventional chondrosarcoma shows resistance to chemotherapy and radiotherapy, posing a major treatment challenge. Novel approaches targeting IDH mutations-present in ~65% of cases-offer promise, with ivosidenib now recommended in NCCN guidelines for IDH1-mutant disease and trabectedin noted in ESMO guidelines for mesenchymal subtypes. Agents like INBRX-109 are emerging to potentially extend PFS with favorable safety profiles in unresectable cases. As no approved therapies exist, advances in molecule-targeted drugs and immunotherapies represent significant opportunities to transform the chondrosarcoma treatment landscape and capture an underserved market segment.

DelveInsight's "Chondrosarcoma Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Chondrosarcoma, historical and forecasted epidemiology as well as the Chondrosarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Discover Key Insights into the Chondrosarcoma Market with DelveInsight's In-Depth Report @ Chondrosarcoma Market Size- https://www.delveinsight.com/sample-request/chondrosarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Takeaways from the Chondrosarcoma Market Report
• The total Chondrosarcoma Market Size in the United States was approximately USD 8.5 million in 2023 and is projected to increase during the forecast period (2024-2034).
• Among the 7MM, the US accounted for the highest incident cases of chondrosarcoma in 2023.
• In 2023, the total Incident cases of Chondrosarcoma were approximately 1,300 cases in the US, which is expected to grow during the forecast period.
• Among EU4 and the UK, France accounted for the highest number of Chondrosarcoma Incident cases, while Spain accounted for the least Incident cases.
• Among the stage-specific incident cases of chondrosarcoma, localized cases contribute the most in Japan.
• As per analysis, Conventional chondrosarcomas represent ∼80% of all chondrosarcomas.
• According to DelveInsight, Chondrosarcoma market size is expected to grow at a decent CAGR by 2032.
• The leading Chondrosarcoma companies such as Akorn, Inc., Epizyme, Inc., Mylan N.V., AbbVie Inc., Abbott, Baxter, Bayer AG, Agios, Inc., Novartis AG, Hoffmann-La Roche Ltd., AEterna Zentaris Inc., Acorn Research Group, Agios Pharmaceuticals, Inc., Infinity Pharmaceuticals, and others.
• Promising Chondrosarcoma Therapies such as Pazopanib, INBRX-109, Trabectedin, AG-120, and others.
• Servier today announced updates to two of its Phase 3 programs evaluating TIBSOVO (ivosidenib tablets) in isocitrate dehydrogenase 1 (IDH1)-mutated cancers. The first patient has been enrolled in the CHONQUER study, a pivotal Phase 3 clinical trial evaluating the efficacy and safety of TIBSOVO versus placebo in patients with IDH1-mutated conventional chondrosarcoma. In addition, the Phase 3 PyramIDH clinical trial has been initiated, and sites are actively recruiting across the globe. The PyramIDH study is evaluating TIBSOVO® (ivosidenib tablets) monotherapy and azacitidine monotherapy in the treatment of patients with IDH1-mutated myelodysplastic syndromes (MDS) who have not previously been treated with a hypomethylating agent.

Stay ahead in the Chondrosarcoma Therapeutics Market with DelveInsight's Strategic Report @ Chondrosarcoma Market Outlook- https://www.delveinsight.com/sample-request/chondrosarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Chondrosarcoma Epidemiology Segmentation in the 7MM
• Total Incident cases of Chondrosarcoma
• Primary Chondrosarcoma cases
• Grade-specific cases of Chondrosarcoma
• Mutation-specific cases of Chondrosarcoma
• Stage-specific cases of Chondrosarcoma

Download the report to understand which factors are driving Chondrosarcoma epidemiology trends @ Chondrosarcoma Prevalence- https://www.delveinsight.com/sample-request/chondrosarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Emerging Chondrosarcoma Drugs
• INBRX-109: Inhibrx
INBRX-109 is the most advanced therapeutic candidate of Inhibrx and is designed to target tumor-biased direct cell death induction by DR5 activation in numerous cancer types. DR5 is a receptor for the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). DR5 activation naturally eliminates damaged and/or neoplastic cells; normal cells are less sensitive to DR5-mediated cell death. INBRX-109 is a tetravalent DR5 agonistic antibody that can potentize DR5 through efficient receptor clustering, causing cell death. Currently, the drug is being evaluated in a potentially registration-enabling Phase II trial, and the company anticipates topline data readout from this pivotal trial by the second half of 2024, which will pave the path to approval in chondrosarcoma by 2025.

• TIBSOVO (ivosidenib): Servier
TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor developed by Servier. A Phase III, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib is underway for participants aged 18 years and older with locally advanced or metastatic conventional chondrosarcoma harboring an IDH1 mutation, whether untreated or previously treated with one systemic treatment regimen. It is expected to be completed by 2031.

Chondrosarcoma Drugs Market Insights
Novel IDH inhibitors like AG-120 (ivosidenib) are showing potential in Phase III trials, particularly for patients with IDH1 mutations, with encouraging clinical activity observed. Additionally, targeting the Hedgehog pathway is being explored, although clinical trial results have been mixed. Inhibitors of the SRC pathway, such as dasatinib, demonstrate therapeutic benefits in preclinical studies, while inhibition of the PI3K-Akt-mTOR pathway shows promise in suppressing tumor progression. Histone deacetylase inhibitors and angiogenesis inhibitors also offer potential avenues for treatment, with ongoing research focusing on their efficacy in chondrosarcoma.

Get In-Depth Knowledge on Chondrosarcoma Market Trends and Forecasts with DelveInsight @ Chondrosarcoma Treatment Market- https://www.delveinsight.com/sample-request/chondrosarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Chondrosarcoma Market Outlook
The current management of chondrosarcoma depends on the type, the grade, and the location of the tumor, while the best predictor of clinical behavior is the grading system from I to III. It is well-established that surgical treatment is the best and the only treatment for chondrosarcoma, as other treatments, such as radiotherapy and chemotherapy, are rendered unresponsive and refractory. Curettage, radical resection, and amputation are the primary surgical treatment options, while these procedures often require considerable judgment and are based on factors such as the size and site of the lesion and its degree of malignancy.

Scope of the Chondrosarcoma Market Report
• Coverage- 7MM
• Chondrosarcoma Companies- Akorn, Inc., Epizyme, Inc., Mylan N.V., AbbVie Inc., Abbott, Baxter, Bayer AG, Agios, Inc., Novartis AG, Hoffmann-La Roche Ltd., AEterna Zentaris Inc., Acorn Research Group, Agios Pharmaceuticals, Inc., Infinity Pharmaceuticals, and others.
• Chondrosarcoma Therapies- Pazopanib, INBRX-109, Trabectedin, AG-120, and others.
• Chondrosarcoma Market Access & Reimbursements, Unmet Needs and Perspectives
• Chondrosarcoma SWOT Analysis and KOL Views

Unlock Strategic Insights with DelveInsight's Comprehensive Chondrosarcoma Market Report @ Chondrosarcoma Market Drivers and Barriers- https://www.delveinsight.com/sample-request/chondrosarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Key Insights
2. Executive Summary
3. Chondrosarcoma Competitive Intelligence Analysis
4. Chondrosarcoma Market Overview at a Glance
5. Chondrosarcoma Disease Background and Overview
6. Chondrosarcoma Patient Journey
7. Chondrosarcoma Epidemiology and Patient Population
8. Chondrosarcoma Treatment Algorithm, Current Treatment, and Medical Practices
9. Chondrosarcoma Unmet Needs
10. Key Endpoints of Chondrosarcoma Treatment
11. Chondrosarcoma Marketed Products
12. Chondrosarcoma Emerging Therapies
13. Chondrosarcoma Seven Major Market Analysis
14. Attribute Analysis
15. Chondrosarcoma Market Outlook (7 major markets)
16. Chondrosarcoma Access and Reimbursement Overview
17. KOL Views on the Chondrosarcoma Market
18. Chondrosarcoma Market Drivers
19. Chondrosarcoma Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

Learn more about the emerging Chondrosarcoma therapies & key companies @ Chondrosarcoma Market Drivers and Barriers- https://www.delveinsight.com/sample-request/chondrosarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Related Reports:

Chondrosarcoma Pipeline Insights 2025
https://www.delveinsight.com/report-store/chondrosarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

"Chondrosarcoma Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Chondrosarcoma market. A detailed picture of the Chondrosarcoma pipeline landscape is provided, which includes the disease overview and Chondrosarcoma treatment guidelines.

Chondrosarcoma - Epidemiology Forecast - 2034
https://www.delveinsight.com/report-store/chondrosarcoma-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

DelveInsight's "Chondrosarcoma - Epidemiology Forecast - 2034" report delivers an in-depth understanding of the Chondrosarcoma, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/ats-conference-coverage

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.